The vaccination is the most effective way to prevent infectious diseases. It allows us to protect ourselves and our fellow citizens. Thanks to the joint efforts of the global medical community, we are now fortunate to have access to SARS-CoV-2 vaccines. This is an essential element in the fight against COVID-19 and will help us stem the pandemic and its effects on our health and society.
Luxembourg's COVID-19 vaccination strategy supports access to and availability of safe and effective vaccines as soon as they are made available on the market.
This will mitigate the health, social and economic consequences of the COVID 19 pandemic. The vaccine will help save lives and make the best use of our resources.
It remains important to follow hygiene rules and wear a mask during the implementation of the vaccination strategy.
Booking an appointment
- You will be invited to the vaccination by post.
- The invitation contains a personalised code that is valid for 2 weeks and cannot be extended!
- Please use this code to make your appointments online via www.covidvaccination.lu.
- The vaccination must be repeated: so please remember to make a second appointment with the same personalised code.
Please note: The vaccination cannot be done in a doctor's office or in a hospital. If it is technically not possible for you to book your appointment online, please contact the Santé helpline: 247-65533.
Do you have an appointment for a vaccination?
Please go to the vaccination centre with your booking confirmation, your social security card (CNS) and your personal ID.
Under this heading you will find information material designed by the Luxembourg government as part of the COVID-19 vaccination campaign.
You can download this material and use it freely for your awareness-raising and information work. Infovaxx is continuously expanded and updated.
Who will be vaccinated in the first phase?
In an initial phase, the vaccine will not be available in sufficient doses for everyone to be vaccinated at the same time. It will therefore be necessary to prioritise.
In managing the COVID crisis, the foremost objective is to protect the health of citizens, especially vulnerable people and those at high risk of infection. The aim is to ensure the best possible medical care for COVID patients and to preserve the capacity of the health system, especially hospitals.
Health professionals and staff working in hospitals and residential facilities for the elderly are among those most exposed to COVID-19, and therefore deserve special consideration and close protection, also to form a sanitary circle around the infected people they care for.
Similarly, people living in residential facilities for the elderly will be vaccinated on a priority basis. Indeed, age and the presence of co-morbidities are non-negligible risk factors.
Prioritisation of other categories of people will be decided upon at a later stage, depending on the availability of additional vaccine doses.
When will the rest of the population be vaccinated?
The rest of the population will be vaccinated according to the availability of vaccines and the vaccination strategy. It is very likely that the vaccination campaign will last for much of 2021.
What is the vaccination process?
Persons identified on the basis of the order of priority to which they are assigned are invited by mail to be vaccinated.
Each invitation includes a personalised access code that allows the beneficiary to connect to an electronic vaccination application.
Citizens can choose their vaccination centre and preferred time slot (subject to availability of appointments). When making an appointment, the citizen must provide some information about his or her state of health.
In addition, people will be able to contact a hotline operated by the Health Directorate to get assistance in the process of making an appointment.
The citizen presents himself with his appointment confirmation letter to the reception desk, which makes a summary check of the information provided and completes it if necessary. The patient then goes to the doctor, who consults the patient's information. The doctor completes the second part of the vaccination questionnaire, chooses the most suitable vaccine, fills in the application and prints the vaccination certificate. If, following the vaccination, the patient experiences any adverse effects in the rest area, he or she will be cared for by staff at the centre and his or her effects will be documented.
Appointments for people with medical vulnerabilities will be arranged in consultation with the person's general practitioner.
Where can I get vaccinated?
Vaccination centres will be set up to ensure geographical distribution throughout the country. The exact locations are currently being determined. For the time being, the following have been selected:
- Site Centre region - Hall Victor Hugo in Luxembourg-Limpertsberg
- Site South region - Maison des matériaux in Belval
Other sites for the Centre-East, North and East regions are being planned. The vaccination centre located in the Centrel region will be the first to open its doors and will thus ensure the first phase of vaccination. All sites will be operational for the arrival of the vaccines.
Why is vaccination important?
Vaccines are considered one of the most important advances in modern medicine and have enabled us to control infectious diseases such as smallpox, polio, cholera, influenza and measles.
The purpose of vaccination is to provide specific protection against a pathogen in order to avoid infection and its consequences in the event of subsequent contact. It provides individual protection against fatal diseases, potentially serious complications or for which there is no curative treatment.
It does not only protect the individual, but also serves to produce "herd immunity" so as to protect vulnerable people and those who cannot be vaccinated.
Vaccines prevent up to 3 million deaths worldwide each year and have contributed to a 65% drop in child mortality since 1990.
How many people need to be vaccinated to achieve herd immunity?
"Herd immunity" is a concept used for vaccination, whereby a population is protected against a given virus once a certain threshold has been crossed. With herd immunity, the vast majority of a population is vaccinated, which reduces the total amount of virus that can spread throughout the population. As a result, not every person needs to be vaccinated to be protected, thus protecting vulnerable groups that cannot be vaccinated.
The percentage of people who must have antibodies to achieve herd immunity to a given disease depends on each disease. For example, herd immunity to measles is achieved when about 95% of a population is vaccinated. The remaining 5% are protected because measles will not spread among those who are vaccinated. For polio, the threshold is about 80%. According to some publications, a threshold of 70% should be reached in order to stop the spread of the SARS-CoV-2 virus. However, a little more hindsight will be needed before we can make a definite statement on this point.
Achieving herd immunity with safe and effective vaccines makes the disease rarer and saves lives.
What are the possible side effects?
Generally speaking, the side effects of vaccines are usually minor. The most common are fever, headache, aches and pains, fatigue or redness in the area where the vaccine is administered. Although unpleasant, these side effects usually subside within one or two days.
Vaccines are medicines. They therefore meet the same requirements for marketing authorisation and safety of use, as well as the same monitoring conditions as other medicines. The European Medicines Agency is responsible for ensuring the safety of vaccines placed on the market.
At the time of marketing, not all of the risks associated with a medicine are always known. This is particularly the case for vaccines against COVID-19. This is why, when the vaccine or medicine arrives on the market and becomes available to a larger number of people, it continues to be constantly monitored and analysed in the light of developments in knowledge and its use in everyday life.
The COVID-19 vaccine deployment plan will pay particular attention to the active monitoring of the safety and efficiency of the vaccine products circulating on the Luxembourg market, through the collection of real-time, medium-term and long-term data. Strict procedures to ensure the traceability of all operations at all levels will be in place and the deployment of the vaccination strategy will be supported by various information systems and computer tools.